261 related articles for article (PubMed ID: 15897239)
1. Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.
Albright CF; Graciani N; Han W; Yue E; Stein R; Lai Z; Diamond M; Dowling R; Grimminger L; Zhang SY; Behrens D; Musselman A; Bruckner R; Zhang M; Jiang X; Hu D; Higley A; Dimeo S; Rafalski M; Mandlekar S; Car B; Yeleswaram S; Stern A; Copeland RA; Combs A; Seitz SP; Trainor GL; Taub R; Huang P; Oliff A
Mol Cancer Ther; 2005 May; 4(5):751-60. PubMed ID: 15897239
[TBL] [Abstract][Full Text] [Related]
2. Discovery of matrix metalloproteases selective and activated peptide-doxorubicin prodrugs as anti-tumor agents.
Hu Z; Jiang X; Albright CF; Graciani N; Yue E; Zhang M; Zhang SY; Bruckner R; Diamond M; Dowling R; Rafalski M; Yeleswaram S; Trainor GL; Seitz SP; Han W
Bioorg Med Chem Lett; 2010 Feb; 20(3):853-6. PubMed ID: 20060717
[TBL] [Abstract][Full Text] [Related]
3. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of the carnosine-gallic acid synthetic peptide on MMP-2 and MMP-9 in human fibrosarcoma HT1080 cells.
Kim SR; Eom TK; Byun HG
J Pept Sci; 2014 Sep; 20(9):716-24. PubMed ID: 24956509
[TBL] [Abstract][Full Text] [Related]
5. Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9.
Kline T; Torgov MY; Mendelsohn BA; Cerveny CG; Senter PD
Mol Pharm; 2004 Jan; 1(1):9-22. PubMed ID: 15832497
[TBL] [Abstract][Full Text] [Related]
6. Metalloprotease-specific poly(ethylene glycol) methyl ether-peptide-doxorubicin conjugate for targeting anticancer drug delivery based on angiogenesis.
Bae M; Cho S; Song J; Lee GY; Kim K; Yang J; Cho K; Kim SY; Byun Y
Drugs Exp Clin Res; 2003; 29(1):15-23. PubMed ID: 12866360
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of a benz[f]indole-4,9-dione analog on cancer cell metastasis mediated by the down-regulation of matrix metalloproteinase expression in human HT1080 fibrosarcoma cells.
Park HJ; Lee HJ; Min HY; Chung HJ; Suh ME; Park-Choo HY; Kim C; Kim HJ; Seo EK; Lee SK
Eur J Pharmacol; 2005 Dec; 527(1-3):31-6. PubMed ID: 16309669
[TBL] [Abstract][Full Text] [Related]
8. Activation of CD95L fusion protein prodrugs by tumor-associated proteases.
Watermann I; Gerspach J; Lehne M; Seufert J; Schneider B; Pfizenmaier K; Wajant H
Cell Death Differ; 2007 Apr; 14(4):765-74. PubMed ID: 17053806
[TBL] [Abstract][Full Text] [Related]
9. Effects of genistein on invasion and matrix metalloproteinase activities of HT1080 human fibrosarcoma cells.
Yan C; Han R
Chin Med Sci J; 1999 Sep; 14(3):129-33. PubMed ID: 12903810
[TBL] [Abstract][Full Text] [Related]
10. Cellular cholesterol regulates MT1 MMP dependent activation of MMP 2 via MEK-1 in HT1080 fibrosarcoma cells.
Atkinson SJ; English JL; Holway N; Murphy G
FEBS Lett; 2004 May; 566(1-3):65-70. PubMed ID: 15147870
[TBL] [Abstract][Full Text] [Related]
11. Expression of integrin alpha(v)beta(3) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo.
Hofmann UB; Westphal JR; Van Kraats AA; Ruiter DJ; Van Muijen GN
Int J Cancer; 2000 Jul; 87(1):12-9. PubMed ID: 10861447
[TBL] [Abstract][Full Text] [Related]
12. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
13. Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases.
Atkinson JM; Falconer RA; Edwards DR; Pennington CJ; Siller CS; Shnyder SD; Bibby MC; Patterson LH; Loadman PM; Gill JH
Cancer Res; 2010 Sep; 70(17):6902-12. PubMed ID: 20663911
[TBL] [Abstract][Full Text] [Related]
14. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP).
Vanhoefer U; Cao S; Harstrick A; Seeber S; Rustum YM
Ann Oncol; 1997 Dec; 8(12):1221-8. PubMed ID: 9496387
[TBL] [Abstract][Full Text] [Related]
15. Type IV collagen induces matrix metalloproteinase 2 activation in HT1080 fibrosarcoma cells.
Maquoi E; Frankenne F; Noël A; Krell HW; Grams F; Foidart JM
Exp Cell Res; 2000 Dec; 261(2):348-59. PubMed ID: 11112341
[TBL] [Abstract][Full Text] [Related]
16. Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery.
Yamada R; Kostova MB; Anchoori RK; Xu S; Neamati N; Khan SR
Cancer Biol Ther; 2010 Feb; 9(3):192-203. PubMed ID: 20023432
[TBL] [Abstract][Full Text] [Related]
17. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
Mansour AM; Drevs J; Esser N; Hamada FM; Badary OA; Unger C; Fichtner I; Kratz F
Cancer Res; 2003 Jul; 63(14):4062-6. PubMed ID: 12874007
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor.
Maquoi E; Noël A; Frankenne F; Angliker H; Murphy G; Foidart JM
FEBS Lett; 1998 Mar; 424(3):262-6. PubMed ID: 9539163
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor-beta1 induces tissue inhibitor of metalloproteinase-1 expression via activation of extracellular signal-regulated kinase and Sp1 in human fibrosarcoma cells.
Kwak HJ; Park MJ; Cho H; Park CM; Moon SI; Lee HC; Park IC; Kim MS; Rhee CH; Hong SI
Mol Cancer Res; 2006 Mar; 4(3):209-20. PubMed ID: 16547158
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of matrix metalloproteinase activity and growth of gastric adenocarcinoma cells by an angiotensin converting enzyme inhibitor in in vitro and murine models.
Williams RN; Parsons SL; Morris TM; Rowlands BJ; Watson SA
Eur J Surg Oncol; 2005 Nov; 31(9):1042-50. PubMed ID: 15993560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
